No Prescription |
 |
 | ||
|
OVRAL L Ovranette |
|
| ||
No Prescription » Prescription Drugs 12 » OVRAL L Ovranette Medication contains 2 hormones (levonorgestrel a progestin and ethinyl estradiol an estrogen). These hormones prevent pregnancy by preventing the release of an egg (ovulation) and changing the womb and cervical mucus to make it more difficult for an egg to meet sperm (fertilization) or attach to the wall of the womb (implantation).Using this medication does not protect you or your partner against sexually transmitted diseases (e.g. HIV gonorrhea).How to use Levonorgestrel-Ethinyl Estradiol OralRead the Patient Information Leaflet provided by your pharmacist before you start using this product and each time you get a refill. The leaflet contains very important information about when to take your pills and what to do if you miss a dose. If you have any questions consult your doctor or pharmacist.Take this medication by mouth once daily or as directed by your doctor. Pick a time of day that is easy for you to remember and take your pill at the same time each day. Pregnancy is more likely if you miss a pill or take a pill late. Make sure you get a new pill pack before you finish your current pack. Also make sure you have back-up birth control (e.g. condoms) available in case you miss a pill.If you have been using another form of hormonal birth control (e.g. patch another type of pill) ask your doctor or pharmacist how to switch to this product.If you are using this medication for the first time and you are not switching from another form of hormonal birth control (e.g. patch ring other birth control pills) take the first pill in the pack on the first day of your period. If your doctor directs you to start this medication on any other day use an additional form of birth control for the first 7 days.Continue taking 1 tablet every day. After taking the last tablet in your old pack start a new pack the next day. There is no break between packs and there are no "reminder" tablets (tablets without medication). Most women do not have regular periods while taking this medication. You may have some bleeding or spotting. If this happens do not stop taking your pills.If you vomit or have diarrhea within 4 hours after taking this medication you may need to use a back-up method of birth control. Consult your Patient Information Leaflet for more information. (See also Missed Dose section.)If you have any stomach upset or nausea with this medication it may help to take it after your evening meal or at bedtime. You may choose to take this medication at another time of day that is easier for you to remember. No matter what time you choose it is very important that you take this medication at the same time each day 24 hours apart. Ask your doctor or pharmacist if you have any questions. Buy OVRAL L Ovranette and other Prescription Drugs 12 products online at Medstore. Buy Online at Medstore - Click Here!
About OVRAL L Ovranette: Product Type: Prescription Drugs 12 OVRAL-L ( Ovranette Generic Ethinyloestradiol/Levonorgestrel ) OVRAL-L (Ovranette Generic Ethinyloestradiol/Levonorgestrel) Ovranette Generic Ethinyloestradiol/Levonorgestrel 0.03/0.15mg Ovranette Generic Ethinyloestradiol/Levonorgestrel OVRAL-L
View more Prescription Drugs 12 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
